Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Intercept Pharmaceuticals (ICPT) Share Price

Press coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.2829532259074 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Intercept Pharmaceuticals (NASDAQ ICPT) opened at $59.90 on Friday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 52-week low of $54.98 and a 52-week high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. During the same period in the prior year, the firm posted ($3.59) EPS. The business’s revenue was up 697.9% compared to the same quarter last year. equities research analysts predict that Intercept Pharmaceuticals will post -13.41 EPS for the current year.

ICPT has been the subject of several research analyst reports. Royal Bank Of Canada assumed coverage on Intercept Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $244.00 price objective for the company. Laidlaw reduced their target price on Intercept Pharmaceuticals from $118.00 to $90.00 and set a “hold” rating for the company in a report on Friday, September 22nd. Cantor Fitzgerald raised Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 target price for the company in a report on Wednesday, November 1st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. Finally, Wedbush reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $153.76.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO David Shapiro sold 1,250 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the transaction, the chief marketing officer now directly owns 45,812 shares in the company, valued at $5,379,703.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,069 shares of company stock worth $325,974. Insiders own 9.20% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply